Glycomimetcs Shares Shoot Up On Announcement Of FDA Breakthrough
Warrior Trading | May 18, 2017 09:22AM ET
Glycomimetc (NASDAQ:GLYC)
GlycoMimetics, Inc. (GLYC), a national clinical stage biotechnology company yesterday announced that they received FDA Breakthrough Therapy Designations for treatment of adult relapsed/refractory acute myeloid leukemia (AML) of the company’s drug candidate GMI-1271.
During a Phase 2 study the drug GMI-1271 achieved better than expected mortality rates in patients with relapsed/refractory AML as well as newly diagnosed patients.
h3 GlycoMimetics, Inc. CMO’s Comments/h3h3 GLYC Technical Analysis/h3
“The FDA’s granting to GMI-1271 of Breakthrough Therapy designation will further help GlycoMimetics to accelerate the development of GMI-1271 as a treatment for this very difficult-to-treat patient population,” said Business Wire
GlycoMimetics Chart
GLYC opened trading yesterday at $5.38 which was up from the previous day’s trading close of $5.37. GLYC closed trading yesterday at $5.37 and spiked up after market to $7.52, equivalent to a 40% increase from the closing price. Taking a look at the daily chart we can see the last time GLYC traded above these levels we have to go back to September 20th, 2016 when it traded at highs of $7.58.
Taking a closer look at the daily chart we can see that before the spike up GLYC had already been in an overall downward trend dating back to August 1st, 2016 when it traded at $8.84. GLYC has a float of 12.22 million shares and traded 1.77 times the normal daily trading volume on Wednesday.
For trading purposes, I would like to see GLYC open trading on Thursday above $6.80 and if it does I would be looking to take a long position at the bell. My stop loss would be $0.20 from my entry position fearing anything more than that and the stock would start to fill in the gap up.
h3 Company Profile/h3GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.
The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.
Get The News You Want
The company has a collaborative research and development agreement with Pfizer Inc. (NYSE:PFE) GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.